ISSN: 2161-0681

Jornal de Patologia Clínica e Experimental

Acesso livre

Nosso grupo organiza mais de 3.000 Séries de conferências Eventos todos os anos nos EUA, Europa e outros países. Ásia com o apoio de mais 1.000 Sociedades e publica mais de 700 Acesso aberto Periódicos que contém mais de 50.000 personalidades eminentes, cientistas de renome como membros do conselho editorial.

Periódicos de acesso aberto ganhando mais leitores e citações
700 periódicos e 15 milhões de leitores Cada periódico está obtendo mais de 25.000 leitores

Indexado em
  • Índice Copérnico
  • Google Scholar
  • Sherpa Romeu
  • Abra o portão J
  • Genâmica JournalSeek
  • JornalTOCs
  • Diretório de Periódicos de Ulrich
  • RefSeek
  • Universidade Hamdard
  • EBSCO AZ
  • OCLC – WorldCat
  • Publons
  • Fundação de Genebra para Educação e Pesquisa Médica
  • Euro Pub
  • ICMJE
Compartilhe esta página

Abstrato

Primary Adenocarcinoma of the Bulbomembranous Urethra: Cause or Coincidence?

Peralta Joao Pedro, Mario Reis, Rabaca Carlos and Amilcar Sismeiro

A 73-year-old male patient was followed in our urology department after prostate cancer in 2004 and bladder cancer in 2011. In April 2013, during the last cystoscopy, a bulbomembranous stricture was found and an urethrotomy was easily performed. Shortly after the procedure, the patient starts complaining of urinary dysfunction and presents with a palpable firm mass in the perineum. An urethrocystoscopy was performed, showing no abnormalities. A pelvic CT-scan was then performed, revealing a complicated and large (6×7×4 cm) post-operative hematoma. After a trial of antibiotics, without any symptomatic improvement, a pelvic MRI showed a large heterogeneous mass, extending to the corporeal bodies and multiple enlarged inguinal and pelvic lymph nodes. He was than submitted to surgical exploration and the pathology report was consistent with primary urethral adenocarcinoma in both the perineum and the corporeal bodies. A new CT scan showed massive metastatic spread. He was proposed for chemotherapy but the prognosis is logically poor.